Clinical Trial

Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with CSU.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-03; most recent amendment 2026-04-06.
Status change: Not Yet Recruiting → Recruiting 2026-04-06
Trial Details
NCT Number NCT07166211
Lead Sponsor Keymed Biosciences Co.Ltd
Conditions Chronic Spontaneous Urticaria (CSU)
Enrollment 48 participants
Start Date 2025-11-27
Primary Completion 2026-11-02 (estimated)
Study Completion 2027-01-14 (estimated)
Updated on ClinicalTrials.gov 2026-04-09